Skip to content

18-002 - Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

Status: open

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy - SWOG S1418 (BR0006)

Treatment for Breast Cancer

Contact Us Or call (251) 445-9834


This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. 


This trial is sponsored by SWOG.

Providers Associated With This Trial

    Principle Investigator

    This link will open in a new tab or window.